PharmAthene was formed in March 2001 to address the urgent biosecurity needs of this Nation and its Allies. Since the terrorist attacks in 2001 and the subsequent deliberate anthrax exposure to the U.S. population, the vulnerability of this Nation to a wide array of threats has come into sharp focus. Additionally, the Nation has recognized how woefully unprepared it is for future attacks.
PharmAthene’s mission is to seize leadership in this emerging field by developing a portfolio of products urgently needed by the U.S. Government and its Allies. To date, PharmAthene has built a solid product pipeline of new human therapeutics and prophylactics for the treatment and prevention of morbidity and mortality from exposure to chemical and biological weapons, and cultivated a strong reputation within the industry. More than $550 million in United States government contract and funding commitments have been awarded to support the Company’s product development programs, which include:
- SparVax® - recombinant protective antigen (rPA) anthrax vaccine
- Valortim® - fully human monoclonal antibody antitoxin – treatment of anthrax
- Recombinant BChE bioscavenger – prevention and treatment of nerve agent poisoning